JP2004529158A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529158A5 JP2004529158A5 JP2002584967A JP2002584967A JP2004529158A5 JP 2004529158 A5 JP2004529158 A5 JP 2004529158A5 JP 2002584967 A JP2002584967 A JP 2002584967A JP 2002584967 A JP2002584967 A JP 2002584967A JP 2004529158 A5 JP2004529158 A5 JP 2004529158A5
- Authority
- JP
- Japan
- Prior art keywords
- hsv
- individual
- pharmaceutical composition
- carrying
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 108091093088 Amplicon Proteins 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 241000700605 Viruses Species 0.000 claims 6
- 230000002950 deficient Effects 0.000 claims 5
- 231100000331 toxic Toxicity 0.000 claims 5
- 230000002588 toxic effect Effects 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 3
- 210000000987 immune system Anatomy 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 239000013598 vector Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28771701P | 2001-05-02 | 2001-05-02 | |
| PCT/IL2002/000345 WO2002087625A1 (en) | 2001-05-02 | 2002-05-02 | Composite oncolytic herpes virus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529158A JP2004529158A (ja) | 2004-09-24 |
| JP2004529158A5 true JP2004529158A5 (enExample) | 2005-12-22 |
Family
ID=23104029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002584967A Pending JP2004529158A (ja) | 2001-05-02 | 2002-05-02 | 混成殺腫瘍ヘルペスウイルスベクター |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1406668A1 (enExample) |
| JP (1) | JP2004529158A (enExample) |
| WO (1) | WO2002087625A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| CA2430589A1 (en) | 2000-11-29 | 2002-07-25 | University Of Rochester | Helper virus-free herpes virus amplicon particles and uses thereof |
| US8092791B2 (en) | 2001-05-23 | 2012-01-10 | University Of Rochester | Method of producing herpes simplex virus amplicons, resulting amplicons, and their use |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| WO2004064765A2 (en) * | 2003-01-23 | 2004-08-05 | University Of Rochester | Herpesvirus amplicon particles |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| GB9816781D0 (en) * | 1998-07-31 | 1998-09-30 | Univ London | Herpes virus vectors for dendritic cells |
| US6774119B1 (en) * | 1999-04-26 | 2004-08-10 | Cedars-Sinai Medical Center | Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells |
-
2002
- 2002-05-02 JP JP2002584967A patent/JP2004529158A/ja active Pending
- 2002-05-02 WO PCT/IL2002/000345 patent/WO2002087625A1/en not_active Ceased
- 2002-05-02 EP EP02766686A patent/EP1406668A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| CN1094642A (zh) | 治疗组合物 | |
| JP2005506957A (ja) | ウイルス性、増殖性および炎症性の疾患の治療のためにビタミンｂ１２およびインターフェロンを用いた複合治療 | |
| JP2003535043A5 (enExample) | ||
| WO2006130553A3 (en) | Hcv protease inhibitors | |
| JP2009504157A5 (enExample) | ||
| JP2004509061A5 (enExample) | ||
| RU2007105354A (ru) | Применение комбинации циклоспорина и пэгилированного интерферона для лечения гепатита с (hcv) | |
| JP2005533021A5 (enExample) | ||
| RU2012136824A (ru) | Способы лечения вирусной инфекции гепатита с | |
| CN102083435A (zh) | 特拉匹韦给药方案 | |
| JP2004529158A5 (enExample) | ||
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| JP2007501806A5 (enExample) | ||
| TWI524895B (zh) | Ｃ型肝炎病毒感染之新治療方法 | |
| EA200900558A1 (ru) | Композиции аполактоферрина и способы их применения в лечении вирусного гепатита с | |
| Larrey et al. | 1054 safety, pharmacokinetics and antiviral effect of BI 207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C | |
| CN103096885A (zh) | 不饱和脂肪酸用于抑制病毒复制和/或感染的用途 | |
| JP2005502585A5 (enExample) | ||
| JP2017514834A5 (enExample) | ||
| Frank et al. | Outbreak of hepatitis B virus infection in an ambulatory haemodialysis clinic in Germany | |
| Flisiak et al. | Effect of lamivudine treatment on plasma levels of transforming growth factor beta 1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B | |
| TWI601531B (zh) | Ｎ－第三丁氧基羰基－３－甲基－ｌ－纈胺醯基－（４ｒ）－ｎ－（（１ｒ，２ｓ）－１－｛［（環丙基磺醯基）胺基］羰基｝－２－乙烯基環丙基）－４－［（４－甲氧基－７－氯異喹啉－１－基）氧］－ｌ－脯氨醯胺之用途 | |
| Niro et al. | Efficacy of lamivudine therapy in chronic delta hepatitis: A multicenter randomized controlled pilot study | |
| Garrison et al. | The Effect of Rifampin on the Pharmacokinetics of Sofos-buvir in Healthy Volunteers: 992 |